Cancer BiologybioRxivPreprint
Dual targeting of PDPK1 and BRAF V600E is synthetically lethal
Tejinder Pal Khaket, Chandrayee Ghosh, Zhongyue Yang…·Electron Kebebew
This study shows that targeting PDPK1 and BRAF V600E together is a potent therapy for anaplastic thyroid cancer, leading to tumor regression through synergistic signaling inhibition and apoptosis.
DOI 10.64898/2026.03.15.711663